NYU Langone Health in the News—Tuesday 24, 2025
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from June 24, 2025.
NYU Langone Health in the News— Wednesday 25, 2025
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from June 25, 2025.
NYU Langone Health in the News — January 26, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from January 26, 2024.
NYU Langone Health in the News— February 22, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from February 22, 2024.
Psychiatry Decision-Making & Reward Research | NYU Langone Health
NYU Langone’s Department of Psychiatry conducts decision-making and reward research.
NYU Langone Health in the News—July 5, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from July 5, 2024.
NYU Langone Health in the News— February 5, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from February 5, 2024.
NYU Langone Health in the News— February 12, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from February 12, 2024.
A Phase 3 Randomized Double-Blind Multicenter Study to Evaluate the Efficacy Safety and Tolerability of Psilocybin in Adults with Major Depressive Disorder
The purpose of this research study is to see if the investigational drug, psilocybin, can help people with major depressive disorder (MDD). This clinical trial s designed to evaluate the safety and efficacy of psilocybin 25 mg versus placebo in adult participants with major depressive disorder (MDD) who are experiencing a depressive episode of at least a 60-day duration. Participants will be randomly assigned to receive a single oral dose of psilocybin 25 mg, psilocybin 5 mg, or inactive placebo, administered with psychosocial support.
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
This study will be a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. The current trial will be conducted across three sites with experience in conducting psilocybin research: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University Grossman School of Medicine (NYU). The proposed double-blind study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin; 30 mg in session 1 and either 30 mg or 40 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week); or 2) oral niacin; 150 mg in session 1 and either 150 mg or 200 mg in session 2, with sessions 1 week apart (total 2 drug exposures separated by approximately one week).